Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Behind the Study: Molecular Characterization of Lung Carcinomas Expressing KK-LC-1

Spotlight

July 11, 2022
Dr. Robert Hsu from the University of Southern California, Norris Comprehensive Cancer Center, describes a recent research paper he co-authored that was published by Oncotarget, entitled, “Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas.” continue reading »

Oncotarget | Role of germline variants in the metastasis of breast carcinomas

News

July 7, 2022
PRESS RELEASE: A new research paper was published in Oncotarget on June 30, 2022, entitled, “Role of germline variants in the metastasis of breast carcinomas.” continue reading »

Oncotarget | Continuous Treatment With Abemaciclib Leads to Sustained and Efficient Inhibition of Breast Cancer Cell Proliferation

News

July 6, 2022
PRESS RELEASE: On July 2, a new research paper was published in Oncotarget, entitled, “Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation." continue reading »

Oncotarget | New Oncology-Focused Papers Published in Volume 13

News

June 23, 2022
PRESS RELEASE: As of June 23, 2022, Oncotarget has published a total of 64 high-impact, oncology-focused papers within Volume 13. continue reading »

Behind the Study: IGF-pathway Biomarkers and Lung Cancer

Oncotarget

June 14, 2022
Dr. Alexander Pohlman from Rush Medical College, Rush University Medical Center, Chicago, IL, describes a recent review published by Oncotarget that he co-authored entitled, “The role of IGF-pathway biomarkers in determining risks, screening, and prognosis in lung cancer.” continue reading »